Heidi has established its regional hub in Singapore following a US$65 million Series B funding round led by Point72 Private Investments. The company plans to build a long-term presence in Southeast Asia and will invest up to US$8 million in Singapore over the next two to three years. This investment will support the creation of local teams across sales, implementation, and clinical partnerships, with an initial hiring target of 10 to 12 roles. As the business grows, Heidi expects to expand further to strengthen customer success, research collaborations, and partnerships with healthcare institutions in the region.
The company’s arrival comes at a time when Singapore faces growing pressure on its healthcare system. By 2030, one in four residents will be aged 65 or older, and the country is projected to have one doctor per 343 residents. These demographic shifts highlight the need for tools that can help ease the workload of clinicians and support care delivery at scale.
Dr Thomas Kelly, CEO and co-founder of Heidi, said Singapore offers a strong foundation for healthcare AI innovation. “For Heidi, Singapore represents more than a market entry, it’s a launchpad for the next phase of healthcare innovation and growth across Southeast Asia,” he said. He added that Singapore’s talent pool, supportive ecosystem, and initiatives such as the TRUST platform for secure and privacy-conscious data sharing make the country well positioned to accelerate responsible AI adoption.
AI-driven tools to boost clinical capacity
Heidi’s platform is designed to automate clinical documentation by transcribing doctor-patient conversations into structured notes. This reduces administrative workloads for clinicians and allows them to dedicate more time to direct patient care. The company has already supported nearly 55,000 consultations in Singapore, demonstrating early demand for tools that increase efficiency in clinical settings.
Dr Sanjeev Shanker, who leads an urgent-care department in Singapore, said the technology has transformed his workflow across multiple languages and clinical scenarios. “My notes are so much more detailed, especially when it comes to procedures and consent taking, and that’s very reassuring from a medicolegal point of view. When I converse with patients in Mandarin, Malay, and even Tamil, it picks it up. Heidi has accomplished three things for me: doing all the typing, giving me more time to talk to patients, and improving both patient and physician satisfaction,” he said.
The platform is gaining traction across primary care, hospitals, and healthcare systems. Osler Group is among the customers using Heidi to automate documentation and support the workload of its clinical teams. Heidi expects wider adoption as more healthcare providers explore how AI can enhance efficiency and improve patient interactions.
Strengthening global momentum
Heidi’s launch in Singapore follows its recent expansion into Hong Kong and adds to its growing international presence. The company’s AI tools currently process more than 2 million patient consultations every week and support 110 languages in 116 countries. The latest funding round brings Heidi’s total capital raised to US$96.6 million, backed by investors including Point72 Private Investments, Blackbird Ventures, Headline, and LocalGlobe.
The new regional hub is expected to play a central role in supporting the company’s growth across Southeast Asia, contributing to product development, clinical research, and market expansion. As healthcare providers look for ways to manage rising demand and clinician shortages, Heidi’s entry into Singapore positions it to support the sector’s move towards scalable and responsible AI solutions.
